Molecular cancer therapeutics
Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.
Daniel R Principe, Jeffrey H Becker, Anastasia E Metropulos, Alejandra M Marinelarena, Thao D Pham, Alexandre F Aissa, Hidayatullah G Munshi
Published: 202610.1158/1535-7163.MCT-25-0483
Abstract
As many as 90% of human pancreatic ductal adenocarcinoma (PDAC) tumors harbor gain-of-function mutations in the KRAS oncogene. Recently, inhibitors of the most common KRAS mutation, KRASG12D, have entered the clinical arena. However, early evidence s…
Preview only. Read the full abstract at the source